AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $14.93 and last traded at $9.90, with a volume of 41869 shares traded. The stock had previously closed at $9.50.
AIM ImmunoTech Trading Up 10.0%
The company has a market cap of $755.43 million, a price-to-earnings ratio of -22.86 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The business’s 50-day simple moving average is $0.09 and its 200-day simple moving average is $0.14.
About AIM ImmunoTech
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than AIM ImmunoTech
- Stock Dividend Cuts Happen Are You Ready?
- Applied Digital: Now the High-Stakes Race to Build Begins
- What is the Dow Jones Industrial Average (DJIA)?
- Zscaler Upgraded: Wall Street Forecasts 26% More Upside
- How Can Investors Benefit From After-Hours Trading
- The Bottom Is in for Powerfleet: An Intelligent Time to Buy
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.
